scholarly journals Screening and large-scale expression of membrane proteins in mammalian cells for structural studies

2014 ◽  
Vol 9 (11) ◽  
pp. 2574-2585 ◽  
Author(s):  
April Goehring ◽  
Chia-Hsueh Lee ◽  
Kevin H Wang ◽  
Jennifer Carlisle Michel ◽  
Derek P Claxton ◽  
...  
2011 ◽  
Vol 28 (3) ◽  
pp. 239-249 ◽  
Author(s):  
Emily T. Beebe ◽  
Shin-ichi Makino ◽  
Akira Nozawa ◽  
Yuko Matsubara ◽  
Ronnie O. Frederick ◽  
...  

2012 ◽  
Vol 30 (1) ◽  
pp. 52-63 ◽  
Author(s):  
Juni Andréll ◽  
Christopher G. Tate

2019 ◽  
Vol 476 (21) ◽  
pp. 3241-3260
Author(s):  
Sindhu Wisesa ◽  
Yasunori Yamamoto ◽  
Toshiaki Sakisaka

The tubular network of the endoplasmic reticulum (ER) is formed by connecting ER tubules through three-way junctions. Two classes of the conserved ER membrane proteins, atlastins and lunapark, have been shown to reside at the three-way junctions so far and be involved in the generation and stabilization of the three-way junctions. In this study, we report TMCC3 (transmembrane and coiled-coil domain family 3), a member of the TEX28 family, as another ER membrane protein that resides at the three-way junctions in mammalian cells. When the TEX28 family members were transfected into U2OS cells, TMCC3 specifically localized at the three-way junctions in the peripheral ER. TMCC3 bound to atlastins through the C-terminal transmembrane domains. A TMCC3 mutant lacking the N-terminal coiled-coil domain abolished localization to the three-way junctions, suggesting that TMCC3 localized independently of binding to atlastins. TMCC3 knockdown caused a decrease in the number of three-way junctions and expansion of ER sheets, leading to a reduction of the tubular ER network in U2OS cells. The TMCC3 knockdown phenotype was partially rescued by the overexpression of atlastin-2, suggesting that TMCC3 knockdown would decrease the activity of atlastins. These results indicate that TMCC3 localizes at the three-way junctions for the proper tubular ER network.


2000 ◽  
Vol 56 (s1) ◽  
pp. s83-s83
Author(s):  
P. Nollert ◽  
M. L. Chiu ◽  
M. C. Loewen ◽  
A. Royant ◽  
H. Behrhali ◽  
...  

2011 ◽  
Vol 175 (2) ◽  
pp. 209-215 ◽  
Author(s):  
Yuguang Zhao ◽  
Benjamin Bishop ◽  
Jordan E. Clay ◽  
Weixian Lu ◽  
Margaret Jones ◽  
...  

2012 ◽  
Vol 423 (1) ◽  
pp. 109-118 ◽  
Author(s):  
Xavier Capdevila-Nortes ◽  
Tania López-Hernández ◽  
Francisco Ciruela ◽  
Raúl Estévez

Biochimie ◽  
1999 ◽  
Vol 81 (6) ◽  
pp. 655-661 ◽  
Author(s):  
Véronique Santoni ◽  
Patrick Doumas ◽  
David Rouquié ◽  
Monique Mansion ◽  
Thierry Rabilloud ◽  
...  

2020 ◽  
Author(s):  
Götz Laible ◽  
Sally Cole ◽  
Brigid Brophy ◽  
Paul Maclean ◽  
Li How Chen ◽  
...  

ABSTRACTTherapeutic monoclonal antibodies (mAbs) represent one of the most important classes of pharmaceutical proteins to treat human diseases. Most are produced in cultured mammalian cells which is expensive, limiting their availability. Goats, striking a good balance between a relatively short generation time and copious milk yield, present an alternative platform for the cost-effective, flexible, large-scale production of therapeutic mAbs. Here, we focused on cetuximab, a mAb against epidermal growth factor receptor, that is commercially produced under the brand name Erbitux and approved for anti-cancer treatments. We generated several transgenic goat lines that produce cetuximab in their milk. Two lines were selected for detailed characterization. Both showed stable genotypes and cetuximab production levels of up to 10g/L. The mAb could be readily purified and showed improved characteristics compared to Erbitux. The goat-produced cetuximab (gCetuximab) lacked a highly immunogenic epitope that is part of Erbitux. Moreover, it showed enhanced binding to CD16 and increased antibody-dependent cell-dependent cytotoxicity compared to Erbitux. This indicates that these goats produce an improved cetuximab version with the potential for enhanced effectiveness and better safety profile compared to treatments with Erbitux. In addition, our study validates transgenic goats as an excellent platform for large-scale production of therapeutic mAbs.


Sign in / Sign up

Export Citation Format

Share Document